Gefitinib enhances the anti‑tumor immune response against EGFR‑mutated NSCLC by upregulating B7H5 expression and activating T cells via CD28H
Affiliations: Zhejiang Provincial Key Laboratory of Media Biology and Pathogenic Control, Central Laboratory, The First Affiliated Hospital of Huzhou University, Huzhou, Zhejiang 313000, P.R. China, Key Laboratory of Cancer Prevention and Therapy Combining Traditional Chinese and Western Medicine of Zhejiang Province, Cancer Institute of Integrated Traditional Chinese and Western Medicine, Zhejiang Academy of Traditional Chinese Medicine, Tongde Hospital of Zhejiang Province, Hangzhou, Zhejiang 310012, P.R. China, Key Laboratory of Integrated Oncology and Intelligent Medicine of Zhejiang Province, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310006, P.R. China, Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences, Shanghai 200031, P.R. China, Department of Blood Transfusion, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310003, P.R. China, Department of Thoracic Surgery, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, Zhejiang 310022, P.R. China
- Published online on: October 6, 2022 https://doi.org/10.3892/ijo.2022.5436
- Article Number: 146
Copyright: © Guo et al. This is an open access article distributed under the terms of Creative Commons Attribution License.